Literature DB >> 9509845

Clinical and microbiologic characteristics of Ochrobactrum anthropi bacteremia.

W L Yu1, C W Lin, D Y Wang.   

Abstract

Ochrobactrum anthropi is an oxidase-positive, nonfermenting, gram-negative bacillus that is an emerging pathogen in immunocompromised patients, particularly in those with indwelling central venous catheters. Reports of clinical manifestation of O. anthropi bacteremia are rare. Herein, we report the clinical and microbiologic characteristics of O. anthropi bacteremia in 15 patients. There were eight males and seven females, whose ages ranged from 1 month to 84 years (mean, 34 years). Ten infections were community acquired. All patients had severe underlying disease and manifested primary O. anthropi bacteremia with no obvious focus. Only three patients had central venous catheters in place at the onset of bacteremia, but none of these showed evidence of catheter-related infection. The mean duration of fever was 4 days (range 0-11) and the mean white blood cell count was 13 x 10(9)/L (range 5.5-28 x 10(9)). All O. anthropi isolates tested were resistant to ampicillin, cephalothin, cefonicid, amoxicillin/clavulanic acid, piperacillin, aztreonam, and ceftazidime, and all were susceptible to gentamicin, amikacin, imipenem, ceftriaxone, and cefoperazone. Most were also susceptible to cefotaxime and moxalactam. Monotherapy with an aminoglycoside or an appropriate beta-lactam (such as cefotaxime or ceftriaxone) yielded good clinical response. None of the 15 patients died directly from O. anthropi bacteremia. Our findings indicate that O. anthropi is often community acquired and can be pathogenic in critically ill or immunocompromised patients with or without indwelling catheters. Although O. anthropi can produce clinically significant infections, the organism seems to be of relatively low virulence.

Entities:  

Mesh:

Year:  1998        PMID: 9509845

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

1.  Septic shock caused by Ochrobactrum anthropi in an otherwise healthy host.

Authors:  Adrien Kettaneh; François-Xavier Weill; Isabelle Poilane; Olivier Fain; Michel Thomas; Jean-Louis Herrmann; Laurent Hocqueloux
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

2.  Genotyping of Ochrobactrum spp. by AFLP analysis.

Authors:  Diana Sara Leal-Klevezas; Octavio Martínez-de-la-Vega; Ector Jaime Ramírez-Barba; Björn Osterman; Juan Pablo Martínez-Soriano; June Simpson
Journal:  J Bacteriol       Date:  2005-04       Impact factor: 3.490

3.  Brucella abortus and its closest phylogenetic relative, Ochrobactrum spp., differ in outer membrane permeability and cationic peptide resistance.

Authors:  J Velasco; J A Bengoechea; K Brandenburg; B Lindner; U Seydel; D González; U Zähringer; E Moreno; I Moriyón
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Clinical characteristics of Ochrobactrum anthropi bacteremia.

Authors:  Hideharu Hagiya; Kouhei Ohnishi; Miyako Maki; Naoto Watanabe; Tomoko Murase
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

5.  Ochrobactrum anthropi Infection of the Hand.

Authors:  Céline Bratschi; Thuan Ly; Andreas Weber; Claudia Meuli-Simmen; Anna Conen; Flavien Mauler
Journal:  J Hand Surg Glob Online       Date:  2020-09-16

6.  Ochrobactrum anthropi - An Emerging Opportunistic Pathogen in Musculoskeletal Disorders - A Case Report and Review of Literature.

Authors:  Madhan Jeyaraman; Sathish Muthu; Prasanna Sarangan; Naveen Jeyaraman; Rathinavelpandian Perunchezhian Packkyarathinam
Journal:  J Orthop Case Rep       Date:  2022-03

7.  The differential interaction of Brucella and ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens.

Authors:  Elías Barquero-Calvo; Raquel Conde-Alvarez; Carlos Chacón-Díaz; Lucía Quesada-Lobo; Anna Martirosyan; Caterina Guzmán-Verri; Maite Iriarte; Mateja Mancek-Keber; Roman Jerala; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno; Esteban Chaves-Olarte
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.